BioSpace News Archive

Regeneron Pharmaceuticals announced the results from its Phase III trial of recently infected asymptomatic COVID-19 patients for its REGEN-COV (casirivimab with imdevimab) antibody cocktail.

AstraZeneca’s diabetes drug Farxiga (dapagliflozin) failed to reach endpoints in a Phase III study as a potential treatment for hospitalized COVID-19 patients serious risk of developing complications.

Six months after a COVID-19 diagnosis, more than 33% of people exhibited some form of brain damage, according to a study appearing in Lancet Psychiatry.

Taysha Gene Therapies has acquired exclusive global rights to TSHA-120, an intrathecally dosed AAV9 gene therapy designed to treat giant axonal neuropathy.

In a flurry of weekend activity, oncology companies showcased the latest clinical and preclinical data for cancer therapies during the virtual American Association for Cancer Research meeting.

The three posters OncoMyx Therapeutics presented at the virtual American Association for Cancer Research (AACR) Virtual Annual Meeting on April 10th provided the first data indicating its myxoma virotherapy approach to oncolytic therapeutics.

Researchers are leveraging the messenger RNA (mRNA) technology used to develop the Pfizer-BioNTech and Moderna COVID-19 vaccines for possible treatments for a range of other diseases, including HIV and cancer.

Recently announced topline results from a Phase II study show SAGE-324, Sage Therapeutics’ investigational oral neuroactive steroid GABAA receptor positive allosteric modulator, significantly reduced tremor score in adult patients with essential tremor.

The new factory will include cutting-edge technology, allowing production of three to four vaccines simultaneously, a massive improvement on the current limitation of one vaccine in an industrial site.

Echosens, a high-technology company offering the FibroScan family of products, announces its presentation (K7), “Modeling the Return on Investment of VCTE for Fatty Liver Disease (FLD) in a General Population Incorporating Device Costs,” at the Academy of Managed Care Pharmacy’s (AMCP) virtual meeting, April 12 - 16, 2021.